VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock.

Several other brokerages have also issued reports on VNRX. Wall Street Zen initiated coverage on VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating for the company. HC Wainwright began coverage on VolitionRx in a research note on Tuesday, April 8th. They issued a "buy" rating and a $2.50 target price for the company. Finally, Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 target price for the company in a research note on Tuesday, June 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, VolitionRx currently has a consensus rating of "Moderate Buy" and an average target price of $3.50.

VolitionRx Trading Up 8.4%

Shares of VNRX stock opened at $0.70 on Thursday. The stock has a market cap of $72.79 million, a P/E ratio of -1.94 and a beta of 1.20. The stock has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.58. VolitionRx has a 1 year low of $0.40 and a 1 year high of $0.94.

Hedge Funds Weigh In On VolitionRx

Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp lifted its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Two Sigma Securities LLC bought a new stake in VolitionRx during the 4th quarter valued at $29,000. Silverberg Bernstein Capital Management LLC raised its holdings in VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after acquiring an additional 60,209 shares during the period. Millennium Management LLC bought a new stake in VolitionRx during the 4th quarter valued at $36,000. Finally, Lagoda Investment Management L.P. raised its holdings in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the period. Hedge funds and other institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.